our Premium Content: News alerts, weekly reports and conference planners

GENE:

EGR1 (Early Growth Response 1)

News alerts, weekly reports and conference planners

10d

A Computational Strategy to Identify Hub Genes in Pathway Analysis of Gamma Tocotrienol-treated MCF-7 Cells and Molecular Docking Study Using Selected Phytochemicals as Therapeutic Agents. (PubMed, Curr Med Chem)

These findings may facilitate the development of traditional medicinebased therapeutic strategies and provide insights for potential lead optimization in breast cancer drug discovery.

10 days ago

Journal

EGR1 (Early Growth Response 1)

Piqray (alpelisib) • Truqap (capivasertib) • Orserdu (elacestrant) • Legalon (silibinin)

13d

Heterogeneity and regulatory mechanisms of ALK-mutant and wild-type epithelial cells in non-small-cell lung cancer: Single-cell transcriptomics and chromatin accessibility. (PubMed, Pharmacology)

ALK mutations drive tumor stemness and drug resistance by blocking epithelial cell differentiation, activating CEACAM6-mediated signaling, enhancing chromatin accessibility, and remodeling the EGR1/PRC regulatory network. Targeting CEACAM6 and its downstream effector EGR1 may represent an effective strategy to overcome ALK-TKI resistance.

13 days ago

Journal

ALK (Anaplastic lymphoma kinase) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CEACAM6 (CEA Cell Adhesion Molecule 6) • SPINK1 (Serine peptidase inhibitor, kazal type 1) • EGR1 (Early Growth Response 1) • MARCKS (Myristoylated Alanine Rich Protein Kinase C Substrate)

ALK mutation

15d

EGR1 Nuclear Condensates Promote Renal Cyst Development in Polycystic Kidney Disease. (PubMed, Exploration (Beijing))

Disruption of EGR1 phase separation significantly alleviated cyst growth in the forskolin-induced 3D spheroid model of mIMCD3 cells and MDCK cyst model. These findings demonstrate that phase separation-mediated EGR1 condensates facilitate renal cyst development in ADPKD.

15 days ago

Journal

CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • CDK4 (Cyclin-dependent kinase 4) • YAP1 (Yes associated protein 1) • EGR1 (Early Growth Response 1)

16d

Combinational Inhibition of the eIF4F Complex, AKT1, and EZH2 Enhances Anticancer Effects in BRAFV600E Mutant A375 Melanoma Cells. (PubMed, Oncol Res)

Melanoma A375 (vemurafenib [VEM]-sensitive) and A375R (VEM-resistant) cells were exposed to eIF4Fi RocA at varying doses and durations in vitro...Combined CR-1-31-B, EZH2i, and AKT1i effectively overcame resistance to RocA and VEM resistance both in vitro and in vivo. The eIF4F complex inhibitor reactivates ERK1/2-EZH2 and AKT1 signaling pathways, resulting in resistance to both eIF4Fi and VEM. Combined administration of an eIF4Fi with EZH2 and AKT1 inhibitors effectively enhances sensitivity to both eIF4F complex and BRAF inhibitors.

16 days ago

Journal • IO biomarker

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • MCL1 (Myeloid cell leukemia 1) • EGR1 (Early Growth Response 1) • EIF4G1 (Eukaryotic translation initiation factor 4 gamma, 1) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2) • JUN (Jun proto-oncogene)

BRAF V600E • BRAF V600

Zelboraf (vemurafenib) • CR-1-31-B

18d

Inhibition of PADI2-mediated vimentin citrullination alleviates silica-induced pulmonary fibrosis in mice. (PubMed, Part Fibre Toxicol)

Pharmacological inhibition or genetic knockout of Padi2 attenuated silica-induced lung inflammation and fibrosis. These findings suggest that targeting PADI2 may represent a novel therapeutic strategy of silicosis.

18 days ago

Preclinical • Journal

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • VIM (Vimentin) • IL1B (Interleukin 1, beta) • EGR1 (Early Growth Response 1)

19d

Integrated transcriptomics and molecular docking identify hub genes and statin regulators in Helicobacter pylori-associated gastric mucosal pathogenesis. (PubMed, Front Cell Infect Microbiol)

To explore potential therapeutic interventions, we performed small-molecule drug prediction and molecular docking for hub genes revealed: Simvastatin: Linked to CCL20, NFKBIA, and ICAM1. Atorvastatin: Associated with CDKN1A, ICAM1, and TNF. TPCA-1: Targeting JAK1. These findings provide a theoretical foundation for further investigation into the molecular mechanisms underlying H. pylori-related diseases.

19 days ago

Journal

BRCA1 (Breast cancer 1, early onset) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • BIRC3 (Baculoviral IAP repeat containing 3) • JAK1 (Janus Kinase 1) • TNFAIP3 (TNF Alpha Induced Protein 3) • CCL20 (C-C Motif Chemokine Ligand 20) • ICAM1 (Intercellular adhesion molecule 1) • IRF1 (Interferon Regulatory Factor 1) • ITGAM (Integrin, alpha M) • SPI1 (Spi-1 Proto-Oncogene) • ETS1 (ETS Proto-Oncogene 1) • IL17A (Interleukin 17A) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • NFKBIA (NFKB Inhibitor Alpha 2) • NFKBIE (NFKB Inhibitor Epsilon) • TRAF1 (TNF Receptor Associated Factor 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • E2F1 (E2F transcription factor 1) • EGR1 (Early Growth Response 1) • HSF1 (Heat Shock Transcription Factor 1) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit)

simvastatin • atorvastatin

23d

Loss of Early Growth Response Protein 1 in the Liver Leads to Hepatic Lipid Accumulation Driven by an Imbalance Between Fatty Acid β-Oxidation and Oxidative Phosphorylation. (PubMed, Gastro Hep Adv)

Fasting-induced hepatic lipid accumulation indeed indicated reduced fatty acid oxidation efficiency upon ablation of EGR1. Hepatic EGR1 deficiency significantly alters lipid metabolism and mitochondrial function, indicating a role of EGR1 in regulating the balance between mitochondrial fatty acid β-oxidation and respiration in the liver.

23 days ago

Journal

EGR1 (Early Growth Response 1)

26d

Glycolytic-inflammatory crosstalk mediated by Glyco-PMF-Rux hub genes drives PMF progression and ruxolitinib resistance. (PubMed, Genes Genomics)

STAT1, EGR1, FOXO1, and SMAD7 are associated with glycolytic-inflammatory crosstalk underlying PMF progression and ruxolitinib resistance, with experimental validation supporting STAT1 and EGR1 as potential diagnostic and therapeutic targets.

26 days ago

Journal

STAT1 (Signal Transducer And Activator Of Transcription 1) • SMAD7 (SMAD Family Member 7) • EGR1 (Early Growth Response 1)

Jakafi (ruxolitinib)

CAR-NK Cells (CL-NK-003) in Pancreatic Cancer (clinicaltrials.gov)

P1, N=9, Recruiting, Changhai Hospital

1 month ago

New P1 trial • First-in-human

EGR1 (Early Growth Response 1)

Ganglioside GM2 induces epithelial-mesenchymal transition (EMT) in cancer cells in a MEK/ERK/Egr1-dependent transcriptional program. (PubMed, J Biol Chem)

Finally, Egr1 KO in HeLa cells further reduced the induction of mesenchymal marker expression in the presence of GM2, thereby confirming the role of Egr1 in GM2-induced EMT (epithelial-mesenchymal transition) process. Taken together, this study identified MEK-ERK-Egr1 axis as an important regulatory signaling in GM2-mediated EMT and pro-tumorigenic functions.

1 month ago

Journal

TGFB1 (Transforming Growth Factor Beta 1) • EGR1 (Early Growth Response 1)

In vivo multiplexed modeling reveals diverse roles of the TBX2 subfamily and Egr1 in Kr as-driven lung adenocarcinoma. (PubMed, Genes Dis)

Transcriptomic analyses of Egr1-deficient tumors suggested immune dysregulation, including heightened inflammation and potential markers of T cell exhaustion in the tumor microenvironment. These findings indicate that Egr1 may play a role in suppressing tumor growth through modulating immune dynamics, offering new insights into the interplay between tumor progression and immune regulation in lung adenocarcinoma.

1 month ago

Preclinical • Journal

RB1 (RB Transcriptional Corepressor 1) • TNFAIP3 (TNF Alpha Induced Protein 3) • ATF3 (Activating Transcription Factor 3) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • EGR1 (Early Growth Response 1)